A month after announcing the withdrawal from its Phase 3 Alzheimer’s trials, biopharma firm Biogen (NASDAQ: BIIB) on Wednesday reported first-quarter earnings that surpassed Wall Street expectations. The company reported adjusted earnings of $6.98 per share, higher than the street projection of $6.88 per share.
On a GAAP basis, earnings grew 29% to $7.15 per share.
Revenue grew 11% to $3.49 billion, but missed the target of $3.38 billion set by analysts. The topline was primarily boosted by its Spinal Muscular Atrophy drug Spinraza as well as its biosimilars.
Revenue from Spinraza grew 10% year-over-year to $518 million. Meanwhile, Multiple Sclerosis drug Tecfidera showed only 1% growth to $999 million, hurt by cut-throat competition from peers.
CEO Michel Vounatsos said, “We are building depth in neuromuscular diseases and movement disorders, and our proposed acquisition of Nightstar Therapeutics would provide us with two potentially first-in-class mid- to late-stage clinical assets in specialty ophthalmology.”
READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS
The results sent the stock up 0.78% during pre-market trading on Wednesday. The stock is currently trading near a multi-year low, hurt by its decision to withdraw from the phase 3 clinical trial.
Biogen was pinning its hopes on Alzheimer’s drug candidate aducanumab for a potential blockbuster product as it already faces intense competition on multiple sclerosis and spinal muscular atrophy fronts. With the failure of aducanumab, the biopharma giant now needs to come up with a renewed strategy to diversify its pipeline.
The news had wiped off $18 billion from Cambridge, Massachusetts-based firm.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
KB Home’s Q3 results expected to benefit from built-to-order model, stable demand
KB Home (NYSE: KBH) has been resilient to challenges like high mortgage rates and the inflation-induced strain on family budgets, while benefitting from the recovery in the housing market. When
Signet Jewelers (SIG) reports lower Q2 2025 sales and adj. profit
Signet Jewelers Limited (NYSE: SIG) has reported a decline in net sales and adjusted earnings for the second quarter of 2025. Same-store sales declined 3.4% during the three months. Net
Adobe reports higher Q3 revenue and earnings; results beat estimates
Design software maker Adobe Inc. (NASDAQ: ADBE) on Thursday reported an increase in third-quarter 2024 revenue and earnings. The results also topped expectations. Third-quarter revenues came in at $5.41 billion,